Activation of peroxisome proliferator-activated receptor (PPAR)- which regulates lipid metabolism in peripheral tissues such as the liver and skeletal muscle, decreases circulating lipid levels, thus improving hyperlipidemia under fasting conditions. Recently, postprandial serum lipid levels have been found to correlate more closely to cardiovascular diseases than fasting levels, although fasting hyperlipidemia is considered an important risk of cardiovascular diseases. However, the effect of PPAR activation on postprandial lipidemia has not been clarified. In this study, we examined the effects of PPAR activation in enterocytes on lipid secretion and postprandial lipidemia. In Caco-2 enterocytes, bezafibrate, a potent PPAR agonist, increased mRNA expression levels of fatty acid oxidation-related genes, such as acyl-CoA oxidase, carnitine palmitoyl transferase, and acyl-CoA synthase, and oxygen consumption rate (OCR) and suppressed secretion levels of both triglycerides and apolipoprotein B into the basolateral side. In vivo experiments revealed that feeding high-fat-diet containing bezafibrate increased mRNA expression levels of fatty acid oxidation-related genes and production of CO 2 and acid soluble metabolites in enterocytes.
Introduction
Peroxisome proliferator-activated receptor(PPAR)- is involved in regulation of fatty acid oxidation in various peripheral tissues including the liver and skeletal muscle [1] . PPAR is among nuclear receptors that are ligand-dependent transcriptional factors inducing mRNA expression of target genes [2] . PPAR activation enhances fatty acid oxidation by inducing mRNA expression of fatty acid oxidation-related genes such as acyl-CoA synthase (ACS), carnitine palmitoyl transferase (CPT), and acyl-CoA oxidase (AOX) [2, 3] . The PPAR-dependent enhancement of fatty acid oxidation decreases the levels of circulating and accumulating lipids. This is why synthetic PPAR agonists such as fibrates have been widely used as anti-hyperlipidemic drugs [4] . We have identified and analyzed food-derived compounds that activate PPAR. [5] [6] [7] [8] . These compounds decrease the amounts of lipids accumulated in hepatocytes in vitro and suppress development of fatty liver in vivo. Moreover, we have reported that fatty acid oxidation in adipocytes is induced by PPAR activation, thereby suppressing lipid accumulation [9] . Therefore, PPAR activation is considered to be valuable for prevention and improvement of metabolic syndrome.
High serum lipid levels under fasting conditions have been considered a risk of cardiovascular diseases [10] . Many studies have revealed that serum lipid levels under postprandial conditions, rather than under fasting conditions, strongly correlate with the risk of cardiovascular diseases [11] . After absorption and resynthesis of triglycerides (TGs) in enterocytes, TGs are assembled into chylomicrons together with apolipoprotein B (ApoB).
The chylomicrons assembled in enterocytes are transported through lymph vessels. It has been elucidated that intestinal lipid absorption and chylomicron production require CD36 [12] .
Disruption of CD36 suppresses the secretion of lipids from enterocytes [13] . Therefore, intestinal lipid metabolism is indispensable for regulation of serum lipid levels in addition to hepatic lipid metabolism.
In this study, we examined the effects of PPAR activation in enterocytes on intestinal fatty acid oxidation and postprandial lipidemia. Treatment with bezafibrate, a synthetic 4 PPAR agonist, increased the mRNA expression levels of fatty acid oxidation-related genes and oxygen consumption rate (OCR) and inhibited lipid transport into the basolateral side in in vitro experiments using Caco-2 cells. Moreover, administration of bezafibrate also enhanced fatty acid oxidation in enterocytes and suppressed postprandial lipidemia in in vivo experiments using high-fat-diet (HFD)-fed mice. These findings indicate that PPAR activation in enterocytes results in suppression of postprandial lipidemia by enhancement of fatty acid oxidation, suggesting that intestinal fatty acid oxidation is a novel target of PPAR treatment for prevention and improvement of hyperlipidemia.
Materials and Methods

Chemicals and cell culture
Bezafibrate was purchased from Sigma (MO, USA) and dissolved in DMSO as a stock solution. All other reagents were from Sigma or Nacalai Tesque (Kyoto, Japan) and guaranteed to be of reagent or tissue-culture grade.
Human Caco-2 cells were purchased from American Type Culture Collection (ATCC) and cultured in DMEM (100 mg/dL glucose) containing 10% FBS, 1% nonessential amino acid solution, and 10 mg/mL penicillin/streptomycin at 37 °C in 5% CO 2 /95% air under a humidified condition. After seeding, Caco-2 cells were seeded at a density of 340,000 cells/mL on 12-well Traswell plates (Corning Inc., MA, USA) for 2 weeks for differentiation into enterocyte-like cells. For the evaluation of differentiation of Caco-2 cells, we measured intestinal alkaline phosphatase activity and transepithelial electrical resistance (TER). There was no significant change in these differentiation markers in all experiments (data not shown).
Twenty-four hours before starting the experiments, apical medium was changed to DMEM containing 50 M bezafibrate, 600 M taurocholic acid Na salt hydrates, and 500 M oleic acid. At the same time, basolateral medium was also changed to serum-free DMEM. For
ApoB and TG measurements, basolateral medium was collected. 5 
Animal experiments
Nine-week-old male C57BL/6 mice were purchased from Clea Japan (Tokyo, Japan).
The mice were maintained under a constant 12-h light/dark cycle. The mice were maintained for 7 days on a standard diet and then divided into 2 groups with the same average body weight and serum TG level. Each group was maintained on 60% HFD or HFD containing 0.2% (w/w) bezafibrate for 7 days. The energy intake of all the mice was adjusted by pair feeding. Thus, the levels of food intake of each group were almost the same (average food intakes were 2.88±0.18 and 2.60±0.17 g/day in the control HFD-fed and 0.2% bezafibrate-fed mice, respectively). 
Real-time quantitative RT-PCR
Total RNA samples were prepared from Caco-2 cells and enterocytes using Sepasol
Super-I (Nacalai Tesque) and an SV total RNA isolation system (Promega, WI, USA), respectively, in accordance with each manufacturer's protocol as previously described [14] .
To quantify mRNA expression, PCR was performed using a fluorescence temperature cycler (LightCycler System: Roche Diagnostics, Mannheim, Germany), as described previously [15] .
Primer sets were designed using a PCR primer selection program at the web site of the Virtual Genomic Center from the GenBank database and the sequences were described in our 6 previous reports [5, 6] . To compare mRNA expression level among samples, the copy number of each transcript was divided by that of 36B4 showing a constant expression level. All mRNA expression levels are presented as the percentage of the control in each experiment.
Measurements of ApoB and TG
For measurement of ApoB amount, ELISA was performed using an anti-human lowdensity lipoprotein APO-B antibody (Clone 12G10; Monosan, Uden, Netherland), affinity purified anti-apolipoprotein B (Rockland, PA, USA), and HRP-conjugated anti-goat IgG (Promega) as the capture, primary, and secondary antibodies, respectively. Details of procedures were previously described [16] . HRP activity was detected using TMB peroxidase substrate (KPL, MD, USA). Purified human very low-density lipoprotein (VLDL; Chemicon Millipore, MA, USA) was used as the standard protein. For measurement of TG amount, we used triglyceride E Test WAKO (Wako, Osaka, Japan).
Determination of OCR
OCR indicative of mitochondrial respiration was determined using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, MA, USA). The XF24 device created a transient 7 μl chambers above target cells in which cells were monitored in real-time as previously reported [17] . Caco-2 cells were cultured for 2 weeks on the customized Seahorse 24-well plates (Seahorse Bioscience, MA, USA). Differentiated Caco-2 cells were incubated in prewarmed XF24 assay medium for 1 h. The assay media consisted of DMEM containing 10% FBS, 1 mM l-glutamine, 1 mM sodium pyruvate, 3.7 g/l NaCl, and 25 mM glucose.
OCR was calculated by plotting the oxygen tension of the medium in the chamber as a function of time (pmol/min). OCR (pmol/min) was divided by protein amount in each well.
Immunoblottings
Immunoblottings were carried out as previously described [14, 15] . The anti-mouse 
Measurement of fatty acid oxidation
The collected enterocytes harvested from the control or bezafibrate-containing HFD-fed mice were incubated in DMEM containing 200 μM palmitic acid, 0.005% fatty-acid-free BSA, 200 μM 1-carnitine, and [ 14 C]-palmitic acid (1 μCi) (American Radiolabeled Chemicals, MO, USA) for 2 h. Fatty acid oxidation products were assessed as previously described [9] with modification. Briefly, the labeling medium containing enterocytes was transferred to a 50-ml polypropylene tube. An uncapped 2-ml sample tube containing a piece of filter paper soaked in 3 N NaOH was placed inside a 50-ml sample tube.
After the tube was sealed, 200 μl of 12 N HCl was added to the medium sample to release 
Statistical analysis
The data were presented as means ± S.E.M. and statistically analyzed using one-way ANOVA when their variances were heterogeneous and unpaired t-test. Differences were considered significant at P <0.05. 
Results
Treatment with bezafibrate increases mRNA expression levels of fatty acid oxidation-related genes in Caco-2 cells and suppresses TG secretion into the basolateral side.
To examine the effects of PPAR activation on enterocytes, we first performed in in vitro experiments using Caco-2 cells. Expression of PPAR mRNA was detectable and constant throughout our experimental period (data not shown). Differentiated Caco-2 cells treated with 50 M bezafibrate for 24 h showed significant increases in mRNA expression levels of fatty acid oxidation-related genes such as ACS, CPT1A, and AOX, as shown in Fig.   1A . These findings suggest that bezafibrate treatment increased fatty acid oxidation in Caco-2 cells. Indeed, OCR was significantly increased by bezafibrate treatment (Fig. 1B) . Under the same conditions, TG secretion into the basolateral side of Transwell plates was suppressed (Fig. 1C) . Secretion of the ApoB protein, which is a component of chylomicrons that transports food-derived lipids, was also suppressed by bezafibrate treatment (Fig. 1D ). These findings indicate that bezafibrate treatment suppressed TG secretion by increasing mRNA expression levels of fatty acid oxidation-related genes in Caco-2 cells, suggesting that enhancement of fatty acid oxidation suppresses TG secretion in enterocytes.
Feeding of bezafibrate enhances mRNA expression levels of fatty acid oxidation-related genes and fatty acid oxidation in intestinal epithelial cells of mice.
To examine the in vivo effects of PPAR activation on TG secretion, C57BL mice were fed HFD containing 0.2% bezafibrate for 7 days. Bezafibrate treatment resulted in the increase in the mRNA expression levels of fatty acid oxidation-related genes such as ACS, CPT1A, and AOX in enterocytes, although the increase of CPT1A and AOX mRNA expression was not statistically significant, as shown in Fig. 2 . Protein expression level of AOX was increased as shown in Fig. 2D . Measurements of fatty acid oxidation using [ 14 C]-labeled palmitic acid revealed that the bezafibrate-treated enterocytes showed increased productions 9 of CO 2 and ketone bodies, which are products of fatty acid oxidation (Fig. 3) . These findings indicate that bezafibrate feeding for 7 days enhances fatty acid oxidation in enterocytes.
Feeding of bezafibrate suppresses postprandial hyperlipidemia in mice.
To study the effects of bezafibrate-induced enhancement of fatty acid oxidation on postprandial lipidemia, plasma TG concentration was measured after oral administration of olive oil (300 l/mouse). After 16 h fasting to decrease basal TG concentration, olive oil was orally administered and plasma TG concentration was determined every 30 min after the administration. The plasma TG concentration was lower in bezafibrate-fed mice than in control mice throughout the experimental periods as shown in Fig. 4A . Initial peaks of plasma TG concentration 90 min after the administration were 198 and 91.9 mg/dl in the control and bezafibrate-fed mice, respectively. Area under curve (AUC) of plasma TG concentration in bezafibrate-fed mice was smaller than that in control mice (Fig. 4B) . The findings suggest that bezafibrate feeding suppressed postprandial lipidemia through the enhancement of fatty acid oxidation in enterocytes.
Discussion
Hyperlipidemia is considered to be a risk factor for cardiovascular diseases [10, 11] .
The liver mainly regulates circulating amounts of lipids under normal conditions through production and absorption of lipoproteins. However, under postprandial conditions, lipid absorption into and transport from intestinal epithelial tissue are also important for regulating serum lipid levels. Postprandial serum lipid levels have been shown to have a stronger positive correlation with coronary artery disease than the fasting serum lipid levels [11] . Thus, decreasing postprandial serum lipid levels is valuable for prevention of cardiovascular diseases. For suppression of absorption of dietary lipids, pancreatic lipase inhibitors have been used [18, 19] . Orlistat, a pancreatic lipase inhibitor used for the treatment of obesity, is an effective drug for suppressing lipid absorption through intestinal epithelia and preventing weight gain in the treatment of obesity in the primary care setting. However, such inhibition of pancreatic lipase causes fecal urgency, oily spotting, and fatty/oily stool [20] . Our present study indicates that enhancement of fatty acid oxidation in enterocytes suppresses postprandial lipidemia through PPAR activation in mice. Thus far, there has been no report showing such fecal side effects in the case of PPAR agonist administration. Therefore, the present study suggests a possibility that suppression of fatty acid oxidation by PPAR activation is a novel target for prevention of cardiovascular diseases.
We have demonstrated that many food-derived compounds function as PPAR agonists with anti-diabetic and anti-hyperlipidemic effects in various tissues such as the liver and skeletal muscle [5] [6] [7] [8] 21] . Thus far, it has been considered that the activity of such compounds as PPAR agonists contributes to the decrease in TG concentration in the liver, skeletal muscle, and plasma in such mice fed food-derived compound. As described above, enhancing fatty acid oxidation in enterocytes suppresses postprandial lipidemia in mice. Thus, enhancing intestinal fatty acid oxidation might contribute to the improvement of lipid accumulation in the liver and skeletal muscle and/or hyperlipidemia caused by metabolic abnormalities, which was observed in our previous studies using obese diabetic mice, although further investigations are needed to elucidate the contribution. Natural compounds activating PPAR generally show lower activities than synthetic agonists such as bezafibrate [22] . This is because natural compounds are transformed into metabolites that have no effect on the liver before entering the whole-body circulation. In this sense, the intestinal effects of natural compounds before being metabolized in the liver are very significant when considering the functions of food-derived compounds. The present study indicates that we should consider the importance of intestinal lipid metabolism as a primary target of PPAR agonists. Immunoblottings of -actin are indicated as a control. 
Figure legends
